Skip to search formSkip to main contentSkip to account menu

dinutuximab

Known as: Ch 14.18UTC, MAb ch14.18, Ch14.18 Monoclonal Antibody 
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody… 
National Institutes of Health

Related topics

Related topics

9 relations
5 ML dinutuximab 3.5 MG/ML Injection [Unituxin]Antibody-Dependent Cellular CytotoxicityComplement-Dependent CytotoxicityNCIt Antineoplastic Agent Terminology

Broader (1)

Monoclonal Antibodies

Narrower (1)

Unituxin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Dinutuximab: A Review in High-Risk Neuroblastoma
Dinutuximab (ch14.18; Unituxin™) is a chimeric human–mouse monoclonal antibody that binds to the glycolipid antigen… 
2016
2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
AbstractPurposeDinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of… 
Review
2013
Review
2013
Targeted Immunotherapy for High-Risk Neuroblastoma—The Role of Monoclonal Antibodies
OBJECTIVE: To systematically review clinical trials evaluating anti-disialoganglioside (GD2) antibodies in treating high-risk… 
2006
2006
Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes
The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuroectodermal origin, including melanoma… 
2006
2006
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
Purpose: We conducted a phase I trial of interleukin 2 (IL-2) in combination with chimeric 14.18 (ch14.18) and murine R24… 
2005
2005
Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
2001
2001
Follow-up in Neuroblastoma: Comparison of Metaiodobenzylguanidine and a Chimeric Anti-GD2 Antibody for Detection of Tumor Relapse and Therapy Response
Early and correct diagnosis of local tumor recurrence, occurrence of metastases, and therapy response are essential in patients… 
Highly Cited
1999
Highly Cited
1999
The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Granulocyte/macrophage-colony stimulating factor (GM-CSF) is very effective at enhancing antibody-dependent cellular cytotoxicity… 
1996
1996
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
The induction of human antimouse antibodies (HAMA) and human anti-idiotypic (anti-Id) responses in cancer patients receiving… 
Highly Cited
1993
Highly Cited
1993
A mechanism for neutrophil-mediated lysis of human neuroblastoma cells.
Neutrophils mediate the lysis of human neuroblastoma cells coated with human/mouse chimeric anti-GD2 ganglioside antibody ch14.18… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)